Section
This analysis of a randomized trial finds no survival benefit at 15 years for bilateral versus single internal thoracic artery grafting in coronary bypass surgery, highlighting the need for further trials to clarify the multiple arterial gr
A validated polygenic risk score (PRS) independently predicts peripheral artery disease (PAD) and major adverse limb events (MALE) in patients with cardiometabolic disease, adding modest but significant predictive value beyond traditional c
This article reviews a validated clinical risk model predicting arrhythmic events in patients with RYR2-mediated CPVT receiving beta-blockers, facilitating personalized management to reduce life-threatening arrhythmias.
The NATURE trial demonstrates that stent retriever thrombectomy combined with conventional PCI significantly reduces infarct size in STEMI patients with large thrombus burden, without increasing short-term adverse events.
Lepodisiran, an siRNA targeting Lp(a), significantly reduces oxidized phospholipids on apo(a) and apoB, highlighting its therapeutic potential in lowering cardiovascular risk linked to elevated Lp(a).
A novel prime editing screening method enables precise functional classification of LDLR gene variants, enhancing diagnosis and therapeutic strategies for familial hypercholesterolemia.
Anti-PD-1 antibody exacerbates pressure overload-induced heart failure by promoting CXCR3+ CD8+ T cell infiltration, which impairs cardiomyocyte mitochondrial function via granzyme B and perforin. This study identifies a novel immunopathoge
Participation in the GWTG-HF program modestly improves guideline-directed medical therapy intensity and reduces short- and long-term mortality in patients hospitalized for heart failure with reduced ejection fraction.
Large-scale GWAS highlight novel genetic loci influencing childhood blood pressure and heart rate, with polygenic risk scores predicting adult cardiometabolic outcomes, underscoring the importance of early-life genetic determinants in cardi
The VRONI study demonstrates the feasibility and effectiveness of combined biochemical and genetic screening for familial hypercholesterolaemia (FH) in children, revealing a higher FH prevalence than previously reported and supporting natio
This review synthesizes evidence linking short-term exposure to cold and heat extremes with increased heart failure hospitalizations, highlighting mechanistic biomarker studies and telemonitoring findings that elucidate temperature-driven H
This article explores how PUS7-induced pseudouridylation of TGFBI mRNA promotes pulmonary hypertension via epigenetic regulation, revealing promising new therapeutic targets.
Longer hospital arrival times significantly increase both in-hospital and long-term mortality in cardiogenic shock, highlighting the urgent need for regional care coordination and early triage.
A nationwide South Korean study reveals that longer hospital arrival times significantly increase both in-hospital and long-term mortality in patients with cardiogenic shock, emphasizing the need for improved regional healthcare coordinatio
This multicenter study validates the Venous Excess Ultrasound Score (VExUS) as a highly accurate, noninvasive tool to predict right atrial pressure in patients evaluated for pulmonary hypertension, outperforming isolated echocardiographic m
Finerenone significantly slows kidney function decline and reduces cardiovascular risk in hypertensive non-diabetic CKD patients, with manageable safety profiles, supporting its therapeutic role beyond diabetes.
This national English study reveals a significant increase in pre-existing cardiovascular disease among patients at cancer diagnosis over two decades, projecting nearly half will have cardiovascular comorbidities by 2050, underlining urgent
The HELIOS-B trial demonstrates that vutrisiran significantly reduces mortality and cardiovascular events in ATTR-CM patients, with its efficacy unaffected by concurrent use of tafamidis or heart failure medications, supporting its broad th
The REBOOT-PARADOX trial evaluated TAVR plus medical therapy versus medical treatment alone in symptomatic paradoxical low-flow, low-gradient aortic stenosis, showing no definitive mortality benefit but supporting personalized care with tim
Aficamten significantly improves diastolic function and cardiac structure in symptomatic nonobstructive hypertrophic cardiomyopathy, indicating benefits beyond outflow tract gradient reduction.
